In this study, once-yearly ZOL 5 mg significantly increased the LS-BMD in M0CSPC patients with osteoporosis who were introduced to ADT for the first time and significantly decreased the levels of the bone resorption marker TRACP-5b. The gene discussed is ACP5; the disease is osteoporosis.